Cellular Origins expanded its collaboration with Immatics to use Cellular Origins’ automated mobile robotic platform, Constellation, in parts of Immatics’ cell therapy manufacturing workflows. The partners said the aim is to improve scalability and efficiency for next-generation cell therapies as solid-tumor progress depends heavily on manufacturing throughput. The collaboration focuses on integrating automation into manufacturing steps without disrupting clinical development momentum. Immatics emphasized that manual processes limit patient access to approved therapies, while Cellular Origins highlighted that robotic systems can help address throughput constraints. Both companies tied the partnership to the broader need for reproducible, scalable manufacturing capable of supporting potential approvals across more indications and larger patient populations.